Akari Therapeutics Plc - ADR
NASDAQ:AKTX 10:14:24 AM EDT
Regulatory, Earnings Announcements
Akari Reports Q3 Results, Highlights Recent Clinical Progress
Published: 12/11/2020 14:31 GMT
Akari Therapeutics Plc - ADR (AKTX) - Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress.
Akari Therapeutics - Lung Program Being Expanded to Include Inflammatory Lung Conditions With Major Exacerbations, in Addition to Covid-19 Pneumonia.
Akari Therapeutics Plc - Pivotal Phase Iii Study in Patients With Severe Dermatological Condition Bullous Pemphigoid (bp) Planned to Start H1 2021.
Akari Therapeutics Plc - As of September 30, Had Cash of Approximately $12.3 Million, Compared to Cash of $5.7 Million As of December 31, 2019.
Akari Therapeutics - Lung Program Being Expanded to Include Inflammatory Lung Conditions With Major Exacerbations, in Addition to Covid-19 Pneumonia.
Akari Therapeutics Plc - Pivotal Phase Iii Study in Patients With Severe Dermatological Condition Bullous Pemphigoid (bp) Planned to Start H1 2021.
Akari Therapeutics Plc - As of September 30, Had Cash of Approximately $12.3 Million, Compared to Cash of $5.7 Million As of December 31, 2019.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.04
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.04
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00
More details on our Analysts Page.